cabozantinib s-malate · Exelixis · NDA 203756
Cometriq
Earliest generic entry, as listed · earliest of 2 marketed strengths
10 Feb 2032
Blocked by patent: US 11298349, US 12128039, US 9717720.
Listed patents · 7 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11298349 | product | 10 Feb 2032 |
| US 12128039 | product, use U-1617 | 10 Feb 2032 |
| US 9717720 | product | 10 Feb 2032 |
| US 8877776 | substance, product, use U-1617 | 8 Oct 2030 |
| US 11091439 | substance | 15 Jan 2030 |
| US 11091440 | product | 15 Jan 2030 |
| US 11098015 | use U-1617 | 15 Jan 2030 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 203756 · 001 · RLD | capsule, oral | EQ 20MG BASE | 10 Feb 2032 |
| 203756 · 002 · RLD | capsule, oral | EQ 80MG BASE | 10 Feb 2032 |
Expired or delisted (1)
- US 7579473 · substance, product · 14 Aug 2026